Sabadilla 30 Versus Individualised Homoeopathic Medicine in Allergic Rhinitis

AN OPEN-LABEL RANDOMIZED CONTROLLED TRIAL TO COMPARE THE EFFECTIVENESS OF SABADILLA 30 VERSUS INDIVIDUALIZED HOMOEOPATHIC MEDICINE ON ALLERGIC RHINITIS USING ALLERGIC RHINITIS SYMPTOM SCORE (ARSS) - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105934

Enrollment

Registered

2026-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J309- Allergic rhinitis, unspecified

Interventions

Intervention1: SABADILLA 30: potency,dose and repetition will be as per homoeopathic principle, will be administered orally for 3 months. Control Intervention1: Invidualized Homoeopathic Medicine: pr

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 60 years of both genders. 2. Cases meeting the ARIA classification for Allergic rhinitis. 3. Cases having Serum IgE levels more than 200 IU/L. 4. Patients clinically diagnosed with Allergic Rhinitis, presenting with characteristic symptoms such as sneezing, nasal obstruction, rhinorrhea, or nasal itching. 5. Participants must be able to give informed consent, meaning they understand the nature of the study or treatment and agree to participate voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with other chronic respiratory conditions such as asthma, COPD and chronic sinusitis that may confound the assessment of allergic rhinitis. 2. Local causes such as nasal polyps, hypertrophied turbinates should be excluded. 3. Pregnant or Lactating women 4. Cases suffering from uncontrolled systemic illness or life-threatening infections or any vital organ failure 5. Patients currently undergoing other systemic treatments (corticosteroids, or immunotherapy or others) for allergic rhinitis and unwilling to discontinue them. 6. Individuals with psychiatric disorders or substance dependence. 7. Participants undergoing homoeopathic treatment for any other chronic disease for last 6 months. 8. Simultaneous participation in any other clinical trial

Design outcomes

Primary

Measure	Time frame
ARSS (Allergic Rhinitis Symptom Score)Timepoint: assessed at baseline and after 3-months of intervention	—

Secondary

Measure	Time frame
Serum IgETimepoint: assessed at baseline and after 3-months of intervention;Modified Naranjo Criteria for Homeopathy (MONARCH)Timepoint: after 3-months of intervention	—

Countries

India

Contacts

Public ContactDr Muskan

National Institute of Homoeopathy Delhi

ajith.nih@gov.in7907671643

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026